ArticleDigestive diseases and sciences2023
A Population-Based Helicobacter pylori Eradication Strategy Is More Cost-Effective than Endoscopic Screening.
Article in Digestive diseases and sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06216639 (EU4Health Project Eurohelican), which is not on this map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
EU4Health Project Eurohelican: A Single-center Prospective Feasibility Study of the Proposed Test-and-treat Preventive Screening Program in Younger Slovenian Participants Aged 30-34 Years With or Without Helicobacter Pylori Infection
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Guidelines for the management of Helicobacter pylori infection in Japan: 2024 revised edition.Journal of gastroenterology · 2026Guideline
- Burden of gastric cancer attributable to Helicobacter pylori in 27 countries from seven geographic regions in 2022.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Pooled it
- Economic Evaluation of Gastric Cancer Screening Strategies: A Systematic Review.Journal of gastrointestinal cancer · 2025Pooled it
- Comparative effectiveness of genotype-guided and empirical bismuth-containing quadruple therapy forFrontiers in pharmacology · 2026Article
- Controversies in management of Helicobacter pylori infection from a U.S. perspective: population screening and treatment.Minerva gastroenterology · 2025Review
- Article
- Review
- Translating evidence into action: overcoming barriers to gastric cancer prevention in Aotearoa.Journal of the Royal Society of New Zealand · 2025Review
- Review
- Global strategy for prevention of gastric cancer.World journal of clinical cases · 2024Article
- A mathematical simulation model to determine the optimal endoscopic screening strategy for detection of H. pylori-naïve gastric neoplasms.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024Article
- Review
- Total worker healthCurrent opinion in epidemiology and public health · 2024Article
- Evolving Concepts in Helicobacter pylori Management.Gastroenterology · 2024Review
- Health economic evaluation on population-basedChinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHelicobacter pylori (HP) eradication therapy is an efficient primary prevention method to reduce gastric cancer development. In Japan, biennial endoscopic screening for individuals aged 50 years and older is currently conducted as a national gastric cancer prevention program.
aimsWe aimed to evaluate which strategy was the most optimal and cost-effective among HP eradication strategy, annual, biennial, and triennial endoscopic screening, and no screening as a national gastric cancer prevention program.
methodsWe developed a state-transition model for HP eradication strategy, annual, biennial, and triennial endoscopic screening, and no screening using a healthcare payer perspective and a lifetime horizon. We targeted a hypothetical cohort of the Japanese population in their 20 s to 80 s. The main outcomes were costs, quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios, gastric cancer cases, and deaths from gastric cancer. We performed one-way, two-way, and probabilistic sensitivity analyses.
resultsHP eradication strategy was more cost-effective than endoscopic screening at any interval in all age groups. Cost-effectiveness was sensitive to HP infection rate. Cost-effective acceptability curves by Monte Carlo simulations for 10,000 trials demonstrated that HP eradication strategy was 100% cost-effective at a willingness-to-pay threshold of US$50,000 per QALY gained in all age groups. Over a lifetime, HP eradication strategy saves US$28.07 billion, increases 37.16 million QALYs, prevents 4.47 million gastric cancer cases, and saves 319,870 lives from gastric cancer.
conclusionA population-based HP eradication strategy is optimal and cost-effective for a national gastric cancer prevention program in Japan, replacing the current secondary prevention-focused biennial endoscopic screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.